Anaphylaxis

Dentin hypersensitivity (DH) causes sharp, short pain from exposed dentin triggered by chemicals, temperature, or touch. It commonly affects older adults and varies widely in prevalence. This research evaluates the effectiveness of Casein phosphopeptide paste (CPP-ACP) alone or combined with a diode laser called Lasotronix in treating DH, as limited studies have explored this combination. The study involves four groups: one receiving CPP-ACP paste application only, one receiving diode laser therapy only, a third receiving both CPP-ACP and laser treatments, and a control group with no treatment. Lasotronix uses a 635nm wavelength laser designed for safe and effective bio-stimulation and photo-disinfection, while CPP-ACP paste aims to reduce pain by managing dentin sensitivity. Participants aged 25 to 65 with at least one sensitive, vital tooth without decay or defective restoration will be involved. They will undergo treatment and follow-up to assess dentin hypersensitivity over three months. Researchers will monitor pain levels and treatment effects, ensuring safety and adherence to the study protocol throughout the trial period.

This research observes children who took part in the TEMPO clinical trial during their first year of life to understand if their early feeding patterns affect the development of allergies or infections in childhood. The study follows these children up to 7.5 years to gather information on allergic symptoms, infections, and related medical care. It is an observational study without additional treatments or interventions. Participants complete self-administered digital questionnaires every three months using a smartphone, tablet, or computer. These questionnaires collect data on allergies, infections, medication use, medical device use, hospitalizations, and emergency room visits. The study is entirely virtual and decentralized, allowing families to participate remotely. Throughout the study, parents provide information via regular online questionnaires, helping researchers track their child's health over time. The main measurements include parent-reported symptoms, medication or device use, and healthcare visits related to allergies and infections. The study runs until March 2029 and includes children aged 3 to 10 years who completed the original TEMPO study.

Researchers are investigating the long-term outcomes of children and young people who completed an 18-month course of oral immunotherapy (OIT) for peanut, egg, or milk allergy. The study aims to compare changes in health-related quality of life (HRQL) up to 5-15 years after stopping OIT, focusing on participants who achieved remission and those who did not. This observational study involves participants from four earlier clinical trials related to OIT treatment for these allergies. Participants will attend one follow-up visit where several tests and evaluations will take place. These include a blood test to measure specific immunoglobulin E (sIgE) levels related to peanut, egg, or milk allergies, and a skin prick test to assess allergy status using various extracts like histamine, saline, house dust mite, rye grass, and the relevant food allergen. Blood collection may be via venipuncture or fingerprick depending on feasibility. Plasma and blood cells will be stored for future research. During the single study visit, participants will complete allergy questionnaires, and blood and skin tests will be conducted to gather data on immune markers and allergy status. Researchers will measure changes in HRQL and the incidence and severity of allergic reactions over the years following OIT. The visit is expected to last about two hours, and results will help understand the long-term effects of OIT on food allergy remission and quality of life.

The FARE Patient Registry is a prospective observational study focused on collecting detailed health and basic information about individuals living with food allergies. Its purpose is to encourage open sharing of de-identified data and to support participation in clinical trials, ultimately aiming to advance scientific discoveries related to food allergy causes and contributing factors. This registry does not involve any treatment or interventions but gathers real-world experiences from participants with food allergies. It serves as a platform for the food allergy community to contribute data that can help researchers understand the extent and etiology of food allergies. Participants provide their health information and experiences, which are stored in the registry for ongoing research use. The main outcome measured is the creation of a registry that characterizes food allergies and factors influencing their development. The study is observational, with no interventions, and participation can continue until the study end date in August 2027.

Researchers are evaluating Exl-111, a drug studied in a Phase 1 trial involving healthy adults aged 18 to 55. The trial aims to find suitable doses for future research by studying single and multiple ascending doses. It includes two parts: a single ascending dose (SAD) phase and a multiple ascending dose (MAD) phase. The study also compares Exl-111 with placebo and an active comparator called omalizumab. Participants are healthy volunteers with allergic disease markers but no active illness. In Part A (SAD), participants receive a single subcutaneous injection of Exl-111 or placebo and stay in the clinic for 5 days, with follow-up visits through 20 weeks. If safety data supports it, Part B (MAD) begins, where participants receive up to four subcutaneous doses of Exl-111, placebo, or omalizumab every 4 weeks. Participants stay in the clinic for several days around each dose and return for follow-up visits through 28 weeks. Throughout the study, participants undergo safety monitoring for adverse events and pharmacokinetic testing to assess drug levels in the blood. The primary outcome measures include treatment-emergent adverse events through Day 196. Secondary measures assess how the body absorbs and processes Exl-111. Participants complete clinic visits, safety labs, skin prick tests (Part B only), and other assessments to track effects and safety over the full duration of the trial.

Researchers are gathering detailed, standardized information about patients who have experienced anaphylactic reactions to better understand the symptoms, triggers, and management of these severe allergic responses. The study aims to improve diagnosis and long-term care for people affected by anaphylaxis by analyzing data collected over time. This research also explores genetic and biomarker factors that may influence the risk and severity of these reactions. Participants who have had an anaphylactic reaction are observed without receiving any specific treatment through the study. Blood sampling is optional but encouraged, as it helps identify sensitization profiles and possible biological mechanisms behind anaphylaxis. The study collects data over a long period, focusing on risk factors, use of adrenaline, country-specific management differences, and genetic and epigenetic markers related to anaphylaxis. Throughout the study, participants provide information and may undergo optional blood tests to help researchers track changes and outcomes related to their allergic reactions. The primary outcome measures include assessing risk factors over 10 years, along with secondary outcomes such as adrenaline use, biomarker validation, and epigenetic studies. This long-term observation helps enhance understanding of anaphylaxis and guides better prevention and treatment strategies for affected individuals.

Researchers are studying how eosinophils, a type of white blood cell, become activated and their role in immune reactions. Eosinophils often increase with allergies, asthma, parasitic infections, some autoimmune diseases, and rarely tumors, a condition called eosinophilia. While usually without symptoms, eosinophilia can sometimes cause swelling, itching, lung problems, heart disease, or nerve damage due to toxic substances released by these cells. Participants with eosinophil counts above 750/ml or abnormal eosinophil buildup in tissues or skin will have thorough medical exams, blood tests, and possibly additional tests based on age and symptoms. This observational study does not offer experimental treatments but monitors clinical responses and collects blood, bone marrow, tissue, and fluid samples for research. Follow-up includes yearly evaluations and may involve bone marrow biopsies, genetic testing, and leukapheresis for adults. Participants will be involved in detailed clinical evaluations at baseline and annually, with sample collections to study disease mechanisms and immune responses. The study aims to identify causes, biomarkers, and treatment effects on eosinophils. Safety monitoring includes standard care for those needing treatment, while research focuses on immune cell behavior, genetic factors, and long-term effects. Participation duration varies per individual, with ongoing assessments of disease activity and patient-reported outcomes.

Researchers are conducting a study called Acutelines, a large data and biobank project at the University Medical Center Groningen in the Netherlands. It focuses on patients with a wide range of acute medical conditions who present to the Emergency Department. The goal is to improve how acute diseases are recognized and treated, understand their outcomes, and support personalized medicine by collecting detailed clinical data, imaging, and biomaterials over time. Participants have their medical information, including demographics, health status, medical history, vital signs, diagnostic tests, and treatments, systematically collected. Biomaterials such as blood, urine, feces, and hair are gathered from patients who meet certain severity criteria. Data collection occurs during hospital admission, including continuous monitoring, and continues with follow-ups at 3 months, 1 year, 2 years, and 5 years after the initial emergency visit. Throughout the study, various assessments are performed, such as quality of life, physical functioning, mental health, symptoms, and hospital length of stay. Researchers collect data on mortality and other health outcomes for up to 50 years. The study uses digital tools to automate data capture and integrates information from multiple healthcare sources. Participants will be monitored closely during hospitalization and at scheduled intervals afterward to help improve understanding and treatment of acute diseases.

This research aims to understand how co-existing health conditions, medical history, and allergy tests affect the results of allergen provocation tests in children. The study includes children from birth up to 18 years old who are being investigated for allergies to foods or antibiotics. It is a prospective observational study conducted at the Hans Christian Andersen Children's Hospital. Participants undergo oral provocation tests where small, increasing amounts of allergens are given to assess allergic reactions. The allergens studied include antibiotics and a variety of common food allergens such as milk, egg, peanut, hazelnut, sesame, wheat, various nuts, soy, fish, shellfish, and poppy seed. Each child is assigned to a group based on the specific allergen they are being tested for. During the study, data on demographics, co-existing conditions, symptoms, skin prick tests, specific IgE levels, and details from the provocation tests are collected and entered into a database. Researchers will assess the relationship between allergy test results and provocation outcomes over a five-year period. Children will be monitored through these evaluations to better understand allergy responses and test effectiveness.

Snake bites affect thousands of people in Australia each year, with few deaths due to timely medical care and quality first aid. This research investigates and compares two first aid methods—the Pressure Bandage Immobilisation (PBI) technique currently recommended in Australia and a simpler Pressure Pad (PP) technique used internationally. The study aims to determine if the PP method is as effective as PBI in slowing venom movement through the body, which is important for improving first aid guidance. Participants will receive an injection of mock venom in the hand or foot, followed by application of either no first aid, the PBI method, or the PP method. Each technique involves specific bandaging and splinting to immobilize the limb, with pressure carefully controlled around 60mmHg. The study will monitor the flow of the mock venom in each case using nuclear medicine imaging to track its movement through the lymphatic system. During the study, participants will undergo repeated scans to observe how quickly the mock venom reaches regional lymph nodes, with each person experiencing all possible combinations of injection site and first aid method in random order. The primary measure is the time taken for the venom to travel to lymph nodes, monitored over a period spanning a minimum of 12 weeks to a maximum of 18 months. This detailed data will help assess the effectiveness and safety of these first aid techniques to inform future recommendations.